Revenues for the fourth quarter of 2025 reached $30.3 million, an increase from $21.2 million in the prior year period. Full-year 2025 revenues totaled $170.4 million, up from $83.3 million in 2024, primarily driven by $72.9 million in upfront license revenue and $11.8 million in service revenue from the Nippon Shinyaku collaboration, alongside higher Zolgensma and Itvisma royalties. The company reported a fourth-quarter net loss of $67.1 million, or $1.30 per share, compared to a net loss of $51.2 million, or $1.01 per share, in the fourth quarter of 2024. The full-year net loss narrowed to $193.9 million from $227.1 million in the previous year. REGENXBIO ended 2025 with $240.9 million in cash, cash equivalents, and marketable securities, which is projected to fund operations into early 2027.
Research and development expenses for the fourth quarter rose to $59.6 million, bringing the full-year total to $228.3 million. This increase was largely attributed to personnel costs and clinical trial expenses associated with the pivotal trials for RGX-202. General and administrative expenses also increased to $22.4 million for the quarter and $82.9 million for the full year, driven by professional services and corporate advisory fees. The company’s full-year loss from operations was $161.2 million.
The company advanced its Duchenne muscular dystrophy program, reporting that patients treated with the pivotal dose of RGX-202 demonstrated an average improvement of 7.4 points on the North Star Ambulatory Assessment compared to the expected disease trajectory at 18 months. Topline pivotal data for RGX-202 is anticipated in early Q2 2026. In retinal diseases, topline pivotal data for subretinal delivery of sura-vec is expected in Q4 2026. Concurrently, the neurodegenerative pipeline faced regulatory setbacks, with the FDA placing clinical holds on both RGX-111 and RGX-121 following a report of an intraventricular CNS tumor in an RGX-111 trial participant. Additionally, the FDA issued a complete response letter for the RGX-121 Biologics License Application in February 2026.
The post REGENXBIO Q4 2025 Earnings first appeared on AlphaStreet News.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
